Stock AMPE AMPIO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ampio Pharmaceuticals, Inc. Stock

Equities

AMPE

US03209T3077

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 03:19:54 2024-04-18 pm EDT 		5-day change 1st Jan Change
0.242 USD -3.20% Intraday chart for Ampio Pharmaceuticals, Inc. -66.01% -88.20%
Apr. 15 Ampio Pharmaceuticals, Inc.(NYSEAM:AMPE) dropped from S&P TMI Index CI
Mar. 27 Ampio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials (USD)

Sales 2022 - Sales 2023 - Capitalization 1.71M
Net income 2022 -16M Net income 2023 -8M EV / Sales 2022 -
Net cash position 2022 11.88M Net cash position 2023 3.67M EV / Sales 2023 -
P/E ratio 2022
-0.15 x
P/E ratio 2023
-0.19 x
Employees 6
Yield 2022 *
-
Yield 2023
-
Free-Float 98.44%
More Fundamentals * Assessed data

Chart Ampio Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Ampio Pharmaceuticals, Inc.

Ampio Pharmaceuticals, Inc.(NYSEAM:AMPE) dropped from S&P TMI Index CI
Ampio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Top Midday Decliners MT
US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings MT
Top Premarket Decliners MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Ahead of Durable Goods, Consumer Confidence Data MT
Ampio Pharmaceuticals Takes Voluntary Decision to Delist From NYSE American; Shares Plunge Premarket MT
North American Morning Briefing : Stocks Struggle After New Records DJ
Ampio Pharmaceuticals, Inc. Provides Update on Results from Pre-IND Enabling Studies CI
Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech MT
Top Premarket Decliners MT
Top Premarket Gainers MT
Ampio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Ampio Pharmaceuticals, Inc. Contemplates Bankruptcy . CI
Ampio Picks Ascendia Pharmaceuticals to Support OA-201's Clinical Development MT
More news

Analyst Recommendations on Ampio Pharmaceuticals, Inc.

Ampio Pharmaceuticals Takes Voluntary Decision to Delist From NYSE American; Shares Plunge Premarket MT
Wall Street Set to Open Higher as Investors Brace for 75 Basis Point Rate Increase MT
Alliance Global Downgrades Ampio Pharmaceuticals to Neutral From Buy MT
Alliance Global Partners Initiates Ampio Pharmaceuticals at Buy, Sets Price Target at $4.50/Share MT
History shows stocks can weather rate hike cycle RE
More recommendations

Press releases Ampio Pharmaceuticals, Inc.

Thinking about buying stock in Fusion Pharmaceuticals, Aptevo Therapeutics, Blink Charging, Ampio Pharmaceuticals, or Bitcoin Depot? PR
Thinking about buying stock in Aditxt Inc, Ampio Pharmaceuticals, TOP SHIPS, Mullen Automotive, or Oatly Group ? PR
AMPIO PHARMACEUTICALS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) AQ
AMPIO PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K) AQ
AMPIO PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K) AQ
More press releases

Quotes and Performance

1 day-3.20%
1 week-66.01%
Current month-73.70%
1 month-85.60%
3 months-85.68%
6 months-92.34%
Current year-88.20%
More quotes

Highs and lows

1 week
0.14
Extreme 0.135
0.56
1 month
0.14
Extreme 0.135
1.99
Current year
0.14
Extreme 0.135
2.91
1 year
0.14
Extreme 0.135
8.30
3 years
0.14
Extreme 0.135
601.50
5 years
0.14
Extreme 0.135
894.00
10 years
0.14
Extreme 0.135
2 703.00
More quotes

Managers and Directors - Ampio Pharmaceuticals, Inc.

Managers TitleAgeSince
Michael Martino CEO
 Chief Executive Officer 68 21-10-12
Howard Levy CTO
 Chief Tech/Sci/R&D Officer 70 21-10-12
Laura Goldberg LAW
 General Counsel - 13-12-31
Members of the board TitleAgeSince
David Stevens BRD
 Director/Board Member 75 11-05-31
J. Buchi CHM
 Chairman 69 21-10-12
Michael Martino CEO
 Chief Executive Officer 68 21-10-12
More insiders

Quotes

Date Price Change Volume
24-04-18 0.242 -3.20% 15,034
24-04-17 0.25 -16.67% 46,877
24-04-16 0.3 0.00% 32,446
24-04-15 0.3 -51.61% 62,569
24-04-12 0.62 -12.92% 52,785

Delayed Quote OTC Markets, April 18, 2024 at 03:19 pm EDT

More quotes

Company Profile

Ampio Pharmaceuticals, Inc. is a drug discovery and development company. The Company is focused on combining scientific, clinical, and manufacturing capabilities to develop therapies aimed at treating conditions for which limited treatment options exist.
Sector
Biotechnology & Medical Research
Calendar
2024-05-08 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AMPIO PHARMACEUTICALS, INC. Stock Ampio Pharmaceuticals, Inc.
-88.20% 275K
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.30% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.79% 96.07B
ARGENX SE Stock argenx SE
-0.44% 21.66B
BIONTECH SE Stock BioNTech SE
-18.35% 20.77B
GENMAB A/S Stock Genmab A/S
-7.45% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.84% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.59% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+20.86% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. AMPE Stock